Kornimate/medical-research-clean huggingface dataset:
measuring concerns of cancer patients referred to complementary medicine treatment integrated within oncology service

Conditions: Quality of Life

Summary: in 2007, the haifa and western galilee district of the chs set out to test the feasibility of integrating complementary medicine (cm) within the chs oncology service. in 2008, the chs established the integrative oncology program with the goal of addressing patient concerns and improving quality of life parameters during chemotherapy and advanced disease. the study hypothesis is that integrated medicine consultation and treatment provided within the oncology department may improve patients' concerns and well-being.

in 2007, the haifa and western galilee district of the chs set out to test the feasibility of integrating complementary medicine (cm) within the chs oncology service. in 2008, the chs established the integrative oncology program with the goal of addressing patient concerns and improving quality of life parameters during chemotherapy and advanced disease. the study is purposed to assess concerns, needs and perspectives of patients referred to integrative consultation during chemotherapy and/or advanced cancer; to characterize social demographic and health parameters of patients who consult or avoid integrative medicine consultation; to document complementary medicine use prior and during consultation; to assess if complementary medicine consultation and treatment improve patient's concerns and well-being; and to assess oncology provider and integrative practitioner communications issues concerning integrative care.

Eligibility criteria:
inclusion criteria: * patients with cancer diagnosis receiving chemotherapy and/or surgical treatment who are referred by their oncology provider to complementary medicine consultation * age older than 18 years exclusion criteria: * age younger than 18 years

Keywords: quality of life integrative medicine supportive care cancer chemotherapy
superb microvascular imaging in focal nodular hyperplasia

Conditions: Focal Nodular Hyperplasia

Summary: focal nodular hyperplasia (fnh) in liver is the second common benign hepatic tumor. it usually shows hypervascular mass on imaging studies and it is not easy to differentiate with other hypervascular malignant tumor. for diagnosis of fnh, contrast-enhanced ultrasonography (us) has been used to detect 'spoke-wheel sign', which can be typically seen in fnh. however, temporal window of vascular phase using contrast-enhanced us (ceus) is very short (about 10 sec) and coordination of patient's respiration during us exam is absolutely needed. thus, the investigators will use superb-microvascular imaging (smi, toshiba, japan) for detection of 'spoke-wheel sign' in patients with proven fnh, which enable to detect slow micro vascular flow without using ceus. first, to compare the detection rate of 'spoke-wheel sign' between ceus using sonazoid (perfluorobutane, ge healthcare) and smi. second, to compare the accuracy of size measurement between gray-scale us and smi (reference standard: ceus using sonazoid.)

1. to evaluate the detection rate of 'spoke-wheel sign' on ceus using sonazoid and smi (primary outcome). each us findings during exam for patients with fnh were recorded by radiologist. the results were interpreted by consensus using 4 scale bar. 0. absence of 'spoke-wheel sign' 1. mild suspicious of 'spoke-wheel sign' 2. highly suspicious of 'spoke-wheel sign' 3. definite "spoke-wheel sign' 2. to evaluated the accuracy of size measurement for fnh on gray-scale us and smi (reference standard: ceus using sonazoid). to calculate the measurement error between each method and ceus using sonazoid on us images using measurement of maximum diameter of tumor. 3. sample size calculation according to the primary outcome. expecting the detection rate of "spoke-wheel sign" on smi, 20% (known detection rate on ceus using sonazoid, 23.5%), a sample size of 62 patients was required using 95% confidence interval.

Eligibility criteria:
inclusion criteria: 1. patients with biopsy or imaging proven focal nodular hyperplasia exclusion criteria: 1. pregnant women 2. patient's age \> 70 3. egg allergy 4. breast-feeding women

Keywords: focal nodular hyperplasia ultrasonography superb-microvascular imaging contrast-enhanced ultrasonography
preventing pain after surgery

Conditions: Pain, Back; Spinal Stenosis; Disc Herniation; Spondylosis; Spondylolisthesis; Back Injuries

Summary: the present study aims to adapt and modify a brief presurgical acceptance and commitment therapy (act) intervention aimed at preventing the transition to chronic post-surgical pain (cpsp) and reducing long-term opioid use. investigators will then assess the acceptability, feasibility, and preliminary efficacy of the finalized intervention to prevent the transition to cpsp and reduce post-surgical opioid use six months following lumbar spine surgery. finally, investigators will identify psychosocial and psychophysical phenotypes associated with response to this intervention.


Eligibility criteria:
inclusion criteria: * scheduled to undergo fusion, discectomy, vertebroplasty, kyphoplasty, or foraminotomy * age 22 and older * able to communicate fluently in english exclusion criteria: * inability to complete study procedures due to delirium, dementia, psychosis, or other cognitive impairment * have a history of severe neurologic movement disorder * are pregnant or intent to become pregnant during study * have undergone previous spinal surgery * have spinal deformity, pseudarthrosis, trauma, infection, or tumor as primary indication for surgery * have undergone acceptance and commitment therapy in last 2 years

Keywords: chronic pain surgery opioid acceptance and commitment therapy prevention
msot as non-invasive biomarker for diagnosis and monitoring of neuromuscular diseases

Conditions: Neuromuscular Diseases

Summary: the goal of this study is to learn if multispectral optoacoustic tomographs (msot) works to diagnose and follow the course of neuromuscular diseases (nmds) in children. msot scans will be obtained from muscle region to measure hemo/myoglobin, collagen and lipid content/signal and oxygenation in patients with neuromuscular diseases. no additional research activities -other than msot - will be done during this study. existing clinical, laboratory and imaging data from standard-of-care procedures will be correlated with the msot data. the expected total duration of the study is approximately 36 months. repeated measurements will be done to evaluate disease progression and the value of msot in nmd.


Eligibility criteria:
inclusion criteria: patients with neuromuscular disease * children (from birth (infants that are born term) to 18 years of age) participants or consent through authorized guardian * confirmed or suspected diagnosis of a neuromuscular disease (through molecular genetics, biopsy, clinical examination) exclusion criteria: participants: * diagnosis is not consistent with a confirmed or suspected neuromuscular disease * patients with active skin lesions (e.g. infections, trauma) or confirmed genetic disorders (e.g. epidermolysis bullosa) that predisposes to skin lesion * medically unstable patients * tattoo on skin overlying the area to be examined * missing consent form * exclusion due to safety concerns of the investigator (subject who has any condition, including any physical, psychological, or psychiatric condition, which in the opinion of the investigator, would compromise the safety of the subject or the quality of the data and renders the subject an unsuitable candidate for the study) * medication leading to increased light sensitivity
bacterial microbiota characterization on implant-supported peek and titanium provisional abutments

Conditions: Peri-implant Mucositis; Oral Bacterial Infection; Bacterial Resistance

Summary: the aim of this study is to determine the relative abundances of the different bacterial phyla and families in the microbiota present on the surface of peek implant-supported provisional abutments compared to titanium implant-supported provisional abutments, as well as the effect of both materials on the presence of antibiotics resistance genes.

the use of provisional abutments is mandatory during the restorative phase of any implant based oral rehabilitation. the introduction of poly-ether-ether-ketone (peek) for the manufacturing of provisional abutments as an alternative to conventional titanium abutments has opened the restorative spectra, offering the clinician and the patient better aesthetics and adhesive outcomes than its predecessor. however, there is to date no clarity on the impact of peek on the bacterial growth and the specificity of the microbiota on the abutment surface. therefore, the present study aims to determine the relative abundances of the different bacterial phyla and families in the microbiota present on the surface of peek and titanium implant-supported provisional abutments, as well as the effect of both materials on the presence of antibiotics resistance genes. study hypotheses: * h1: the characteristics of the bacterial microbiota present at the connection area of implant-supported provisional abutments are dependent upon the abutment material. * h2: an increased presence of antibiotic resistance genes is found in the bacterial microbiota on titanium provisional abutments when compared to that found on peek abutments. the study uses a metagenomic approach based on the characterization of the bacterial communities, as well as on the sequencing of the 16s gene, and on the other hand, on the sequencing of the high-throughput (hts) of the whole genome, for variations of the antibiotic resistance genes. sample retrieval will be conducted prior to implant placement, at the adjacent teeth gingival sulcus (t0), and two months after provisional abutment (and crown) connection (t1), from the retrieved abutments. patient allocation in the "peek" or "titanium" groups will be randomized. intra- and interpatient comparisons will be conducted. statistical analyses include two-way anova and tukey's post-hoc test, at p\<0.05.

Eligibility criteria:
inclusion criteria: * asa i patients * indication of implant treatment to replace an upper or lower premolar * presence of natural teeth adjacent to the implant region * gingival biotype in the posterior region of 3 to 4 mm exclusion criteria: * immunosuppressed patients * tabacco, alcohol or drug addictions * history of periodontal disease * need of bone grafting in the implant region

Keywords: implant-supported provisional abutment poly-ether-ether-ketone titanium bacterial microbiota antimicrobial resistance genes
clinical trial of autologous adipose derived regenerative cells for the treatment of male stress urinary incontinence

Conditions: Urinary Incontinence , Stress

Summary: the purpose of this study is to evaluate the efficacy and safety of periurethral injection of autologous adipose derived regenerative cells (adrcs) in male stress urinary incontinence.


Eligibility criteria:
inclusion criteria: * males with stress urinary incontinence with insufficient effect by behavioral therapy or pharmacotherapy persisting more than 1 year after either of the following surgical procedure: * patients with symptoms after radical prostatectomy for localized prostate cancer and currently without relapse/metastasis, and psa level less than 0.1 ng/ml for over 1 year * patients with symptoms after transurethral prostatectomy or laser prostatectomy for prostatic hyperplasia, and psa level less than 4.0 ng/ml over 1 year * age of 20 or above * mild to moderate urinary incontinence on the 24-hour pad test * patients who can keep a bladder diary in a satisfactory manner * patients who are willing and able to give signed consent exclusion criteria: * - concurrent with any other types of urinary incontinence * history of urinary or reproductive surgery within 6 months * history of behavioral therapy or pharmacotherapy within 3 months * concurrent with diabetes insipidus * history of radiotherapy in the lower urinary tract * history of adrcs treatment for stress urinary incontinence * history of any type of cell therapy within 6 months * participation in any other clinical trial within 3 months * concurrent with lower urinary tract obstruction * concurrent with urolithiasis, urinary tract infection or interstitial cystitis * history of recurrent urinary tract infection * history of malignant neoplasm within 5 years or a suspicion of it * life expectancy of less than 1 year * any other patients whom the trial investigator deemed ineligible to this study

Keywords: cell transplantation
as-oct evaluation of iridocorneal angle of patients of angle closure glaucoma after phacoemulsification

Conditions: Glaucoma, Angle-Closure

Summary: evaluation of the effect of phacoemulsification and yag laser peripheral iridotomy on the anterior chamber angle anatomic parameters in pacg eyes, using anterior segment optical coherence tomography (ss asoct) device

the recent treatment of acg is phacoemulsification in patients of acute attack with yag laser iridotomy in the other eye. the as-oct will be used for evaluation of the angle of the anterior chamber parameters in both eyes after phacoemulsification and yag laser peripheral iridotomy. follow up of as-oct will be done 1,3,6 months after surgery and we will compare results in each eye and between both eyes. .

Eligibility criteria:
inclusion criteria: * patients with acute attack of angle closure glaucoma in one eye. * patients fit for phacoemulsification exclusion criteria: * 1- patients with history of any intraocular surgery. 2- patients with history of refractive surgery. 3- patients with diabetic retinal vasculopathy or retinal detachment. 4- patients with chronic angle closure glaucoma, open angle glaucoma or 2ry glaucoma
pemetrexed and carboplatin in locally advanced or metastatic breast cancer

Conditions: Breast Cancer; Neoplasm Metastasis

Summary: this is a nonrandomized study of pemetrexed plus carboplatin, with the primary objective of determining the efficacy of the combination in tumor reduction, in patients with locally advanced or metastatic breast cancer.


Eligibility criteria:
inclusion criteria: * histologic or cytologic diagnosis of locally advanced or metastatic breast cancer * no prior chemotherapy for locally advanced or metastatic breast disease. * patient may have received prior adjuvant therapy finished greater than 1 year prior to enrollment. * adequate bone marrow, liver and kidney function * recist criteria for disease status exclusion criteria: * prior treatment with pemetrexed * pregnant or breast feeding * brain metastasis * unable or unwilling to take folic acid, vitamin b12 supplementation, or dexamethasone.
meaning-centered pain coping skills training for cancer pain

Conditions: Advanced Solid Tumor; Pain

Summary: this study is a randomized controlled trial of a psychosocial pain management intervention called, meaning-centered pain coping skills training (mcpc). patients with advanced solid tumor cancer and pain interference (n=210) will be randomized to mcpc or a standard care control condition. patient-reported outcomes will be assessed at baseline and 8- and 12-week follow-ups. the risk and safety issues in this trial are low and limited to those common to a psychosocial intervention (e.g., loss of confidentiality).

many patients with advanced cancer describe pain as a debilitating symptom that greatly interferes with activities they care about. psychosocial interventions show promise for improving cancer-related pain; however, there is a lack of interventions that address existential and spiritual concerns (e.g., a loss of meaning, purpose, and peace) that are common among those facing high levels of pain interference from advanced cancer. to address this need, an intervention called meaning-centered pain coping skills training (mcpc) was developed. in this trial, the investigators will randomize 210 patients to mcpc or enhanced usual care control. patient-reported outcomes will be assessed at baseline and 8- and 12-weeks after baseline. as in the investigators' extensive pilot work, mcpc's four 45-to-60 minute individual weekly sessions will be delivered by trained study therapists via an accessible videoconference format. intervention sessions focus on training participants in evidence-based cognitive-behavioral skills, such as guided imagery and activity pacing. emphasis is placed on using skills to reduce the degree to which pain interferes with participants' sense of meaning, purpose, and peace. the first aim of this trial is to determine the efficacy of mcpc for reducing the primary outcome of pain interference at 8-weeks. the second aim is to determine the efficacy of mcpc for improving secondary outcomes at 8-weeks. the third aim is to test the maintenance of mcpc's effects on primary and secondary outcomes at 12-weeks. the fourth aim is to estimate the cost-effectiveness of implementing mcpc.

Eligibility criteria:
inclusion criteria: * stage iv solid tumor cancer diagnosis * eastern cooperative oncology group (ecog) performance status of 2 or lower * at least one clinical pain severity rating \> 0 out of 10 in past month * at least moderate pain interference (8-item patient-reported outcomes measurement information system \[promis\] pain interference t-score \>/= 55) in the past week at telephone screening * ability to speak and read in english * age \>/= 18 years. exclusion criteria: * significant cognitive impairment as indicated in medical chart or during telephone screening * serious untreated mental illness * primary brain cancer diagnosis * previous engagement in pain coping skills training or meaning-centered psychotherapy * enrollment in hospice at screening

Keywords: caner pain management psychosocial intervention spiritual aspects of coping with pain pain coping skills training meaning-centered psychotherapy
post-stroke triage "doc": simple screening for depression, obstructive sleep apnea and cognitive impairment

Conditions: Transient Ischemic Attack; Stroke; Depression; Obstructive Sleep Apnea; Cognitive Impairment

Summary: the purpose of this study is to determine whether simple, evidence-based clinical screening be quickly and feasibly implemented (\>85% of patients in an average of \<6 minutes) in large-volume urgent transient ischemic attack (tia)/stroke clinics to identify individuals at high risk for the three most common and devastating post-stroke co-morbidities (depression, obstructive sleep apnea and cognitive disorders).

we have created a simple screening tool (the "doc" screen) that will be routinely applied to all patients at a high-volume regional stroke prevention clinic. consenting patients will also undergo "gold standard" research assessments in order to determine the diagnostic characteristics of the screen compared to gold standard research assessments.the proportion of eligible patients who complete doc screening and the time for completion (mean, range, standard deviations) will be calculated from aggregated data for all new consults in the stroke prevention clinic. for patients who consented to undergo gold standard testing, sensitivity, specificity, positive predictive value, negative predictive value and likelihood ratios of the doc screen will be calculated. screening cut-points will be optimized using receiver operating characteristic (roc) and area under the curve analysis, and logistic regression will be applied to this roc curve analysis to control for variables such as age, sex, bmi and education. we hope to develop a pragmatic approach to screening the large, high-risk stroke prevention clinic population, allowing broad screening for these important health conditions. this could change routine standard of care across stroke prevention clinics and facilitate early identification and appropriate assessment of patients.

Eligibility criteria:
inclusion criteria: * attending outpatient tia and stroke prevention clinics at any of the three regional stroke centres. exclusion criteria: * those who are unable to complete the screen complete the screen due to severe aphasia, severe motor dysfunction and those who are not fluent in english without translation available.
radiotherapy dose adaptation based on tumor biology in patients with cn2b-n3 breast cancer

Conditions: Breast Cancer Stage III

Summary: the purpose of the study is to evaluate treatment outcomes of breast cancer with internal mammary or supraclavicular lymph node metastasis according to total radiation dose of postoperative radiation therapy differentiated by tumor response to neoadjuvant chemotherapy. the main questions it aims to answer are: * 5-year disease-free survival * 5-year overall survival * 5-year locoregional recurrence * adverse events after radiation therapy * quality of life participants will be assessed by multi-dimensional methods before and after radiotherapy: * disease status evaluation including physical and radiological examination * quality of life assessment with questionnaires (breast-q) * adverse event assessment according to ctcae version 5.0


Eligibility criteria:
inclusion criteria: * female with age 19 or older * metastasis to internal mammary and/or supraclavicular lymph nodes, assessed by radiological exams and/or biopsy * underwent neoadjuvant chemotherapy * pathologic confirmation of invasive breast cancer treated with breast conserving surgery or mastectomy * eastern cooperative oncology group performance status 0-2 * informed consent exclusion criteria: * previous history of radiation therapy to the chest * distant metastasis
interface pressure measures for matresses: nimbus 3 versus summit

Conditions: Chronic Immobile Patients

Summary: the primary objective of this study is to compare the distribution of pressure among pressure interfaces between two anti-bedsore mattresses.


Eligibility criteria:
inclusion criteria: * the patient must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * bedridden patients that still have some measure of mobility, or that can change beds with assistance. * patients with symmetrical buttox support * body mass index between 16 and 35 exclusion criteria: * the patient is participating in another study * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, under tutorship or curatorship * the patient refuses to sign the consent * it is impossible to correctly inform the patient * strict decubitus dorsal position is contra-indicated * state of agigation or non-cooperation * asymetrical deformation of the spine or hips in the frontal plane * bed sores present * evolving cardiac pathology * recent scar at a pressure interface * deep vein thrombosis * expected life span \< 24 weeks